Multiple Sclerosis
Conditions
Keywords
biomarker, progression, MRI, cognition
Brief summary
By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained
Detailed description
The current study aims to comprehensively investigate the individual clinical, morphological and biochemical aspects of MS in order to elucidate underlying mechanisms leading to disease progression. This shall ultimately serve to identify imaging and biochemical markers, which may support clinical management of persons with MS (pwMS). The following markers will be assessed: demographics (age, sex), clinical (EDSS at baseline, disease duration); neuropsychological (SDMT (Symbol Digit Modalities Test) score); MRI (Magnetic Resonance Imaging) (lesion load, atrophy); Biochemical markers analyzed in cerebrospinal fluid (CSF), blood, DNA, RNA, peripheral blood mononuclear cells (PBMCs)
Interventions
OTHERblood sample
40-50 ml of blood is taken
Sponsors
Medical University of Graz
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with suspected or proven multiple sclerosis * The participants are patients who are in inpatient or outpatient care of the Department of Neurology at the Medical University of Graz, Austria
Exclusion criteria
* Excluded from the examinations are all patients for whom an MRI examination is impossible or problematic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of EDSS ( Expanded Disability Status Scale) progression by combined markers of the disease | a maximum of 4 years | EDSS score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of clinical relapses | a maximum of 4 years | Prediction of clinical relapses |
| Conversion from CIS (Clinically Isolated Syndrome) to MS (Multiple Sclerosis) defined by MRI and clinical criteria | a maximum of 4 years | Conversion from CIS to MS defined by MRI and clinical criteria |
| Time of transition to progressive form of MS | a maximum of 4 years | Time of transition to progressive form of MS |
| Neuropsychological progression (decrease in SDMT performance) | a maximum of 4 years | Neuropsychological progression (decrease in SDMT performance) |
| Increase in morphological damage (lesion load, atrophy) | a maximum of 4 years | Increase in morphological damage (lesion load, atrophy) |
Countries
Austria
Contacts
Primary ContactChristian Enzinger, Prof.
Backup ContactMichael Khalil, MD
Outcome results
None listed